NAPWA

An experimental(Of a drug) Not licensed for use in humans, or as a treatment for a particular condition. Experimental drugs are studied in clinical trials to determine their safety and efficacy, and are sometimes made available via Special Access Schemes prior to their approval. NNRTI, RDEA806, appeared to have strong antiviralA medication or substance which is active against one or more virusesA small infective organism which is incapable of reproducing outside a host cell.. May include anti-HIV drugs, but these are more accurately termed antiretroviralsA medication or other substance which is active against retroviruses such as HIV.. activity and a favourable safety profile in a Phase IIA smaller clinicalPertaining to or founded on observation and treatment of participants, as distinguished from theoretical or basic science. trial designed to establish whether a drug is effective. Phase II studies are conducted to evaluate the effectiveness(Of a drug or treatment). The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the standard procedure, Phase II clinical trials gauge efficacy, and Phase III trials confirm it. of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks. If there is evidence that the drug is effective, a Phase IIIA large clinical trial designed to establish whether a drug is effective and safe enough for widespread use. Phase III studies include expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling. study is undertaken, with a larger number of participaants, to confirm this. study presented at IAS 2008. read more »